Tuesday, 7 July 2020

Novavax Announces $1.6 Billion Funding from Operation Warp Speed

Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure
OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020

GAITHERSBURG, Md., July 07, 2020 (GLOBE NEWSWIRE/Knowledge Bylanes) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. Novavax has been awarded $1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

“The pandemic has caused an unprecedented public health crisis, making it more important than ever that industry, government and funding entities join forces to defeat the novel coronavirus together. We are honored to partner with Operation Warp Speed to move our vaccine candidate forward with extraordinary urgency in the quest to provide vital protection to our nation’s population,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis.”

Under the terms of the agreement, Novavax will demonstrate it can rapidly stand up large-scale manufacturing and transition into ongoing production, including the capability to stockpile and distribute large quantities of NVX-CoV2373 when needed. The agreement will fund the late-stage clinical studies necessary to determine the safety and efficacy of NVX-CoV2373, including a pivotal Phase 3 clinical trial with up to 30,000 subjects beginning in the fall of 2020.

“Adding Novavax’ candidate to Operation Warp Speed’s diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” said U.S. Health and Human Services Secretary Alex Azar. “Today’s $1.6 billion investment supports the Novavax candidate, depending on success in clinical trials, all the way through to manufacturing 100 million doses for the American people.”

Today’s agreement also allows for a follow-on agreement with the U.S. government for additional production and procurement to support OWS’ vaccine production goal. This latest federal funding supports Novavax plans to file submissions for licensure with the U.S. Food and Drug Administration (FDA).

A Phase 1/2 clinical trial of NVX-CoV2373 in 130 healthy participants 18 to 59 years of age began in Australia in May. Preliminary immunogenicity and safety results are expected at the end of July, and the Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin thereafter. The Phase 1/2 clinical trial is being supported by an up-to $388 million funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI).

For further information, including media-ready images, b-roll, downloadable resources and more, click here.

About Operation Warp Speed

Operation Warp Speed is facilitating, at an unprecedented pace, the development, manufacturing, and distribution of COVID-19 countermeasures, between components of Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), FDA, the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA, part of the HHS Office of the Assistant Secretary for Preparedness and Response); the Department of Defense. OWS is coordinate existing HHS-wide efforts, including the NIH's ACTIV partnership for vaccine and therapeutic development, NIH's RADx initiative for diagnostic development, and work by BARDA.

About NVX-CoV2373

NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. A Phase 1 clinical trial of NVX‑CoV2373 initiated in May 2020, with preliminary immunogenicity and safety results expected in July 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) is investing up to $388 million, and Department of Defense (DoD) is investing up to $60 million of funding to advance clinical development of NVX‑CoV2373.

About Matrix-M™

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Minka Development plans to launch its latest and largest projects in East Cairo soon

In light of the current challenges faced by the Egyptian real estate sector

Sallam: The Egyptian real estate sector has proven to be remarkably resilient in comparison to other sectors with great opportunities for growth

Abdullah Salam – CEO of Minka Development – one of the latest Sallam family owned ventures – announced that the company is currently working on putting the final touches of its latest and largest project in East Cairo. The project, planned to be launched during the coming two months, will set a new benchmark for property innovation and livability in the Egyptian real estate market. Moreover, the company plans to expand in West Cairo and coastal areas during upcoming years.

Sallam expressed his pride with the success achieved by the company in creating its own identity. “Minka Development has an extremely simple, yet mindful and challenging agenda, with a clear mission and vision to: Make Egyptians happier and Egypt a better place, by developing meaningful and innovative properties for the privileged and help provide safe and sustainable dwellings for the under privileged.”, mentioned Sallam.

Minka Development’s current projects under development will witness investments exceeding EGP 6 billion in the next four years. During its four short years of operation since 2016, Minka developed a number of successful projects, each of which has its own unique characteristics. They stand out because they cater to untapped customer aspirations, are designed with extreme detail and are delivered ready to live-in or generate income”, added Sallam

"Despite the recent challenges facing the whole world, the Egyptian real estate sector has proven to be remarkably resilient in comparison to other sectors,” said Sallam highlighting that in a time of crisis collaboration is prioritized over competition. “The real estate sector has great opportunities for growth, which we consider a major motive to keep innovating”, commented Sallam

Furthermore, Sallam explained that since the outbreak of the COVID-19 pandemic, Minka Development has applied all safety measures across its headquarters and construction sites, in line with the government’s decision to cautiously sustain the momentum of the economy”. The company has also been keen to pay the salaries ahead of time, and disburse an extra payout to help employees manage any personal surprises too”.

It is worth mentioning that Minka Development is fully owned by the Sallam Family and was established in 2016. The Sallam family have been doing business in Egypt since 1939 more than 80 years ago. They founded and introduced many different brands and businesses to the Egyptian market, including consumer electronics and appliances retailer BTECH, iconic brands such as IDEAL and Olympic Electric, and edutainment giant KidZania, Minlo the manufacturer of TANK and Koldair products, Wasla Outsourcing Services Company, OCL for Warehousing and Logistics, Al Ofok Agricultural, and InPack Industries for Packaging Products, among others, that have all positively impacted the Egyptian economy. The Sallam family are also the founders of the Egyptian Group of Charity Banks—The Egyptian Food Bank, The Cure Bank and The Clothing Bank, which contribute everyday in making people’s lives better.

في ظل التحديات الحالية التي يمر بها قطاع العقارات

سلام: سوق العقارات المصري يحظى بوضع أفضل من القطاعات الأخرى ولديه فرص كبيرة للنمو ونستعد لإطلاق أحدث مشاريع مِنكَ في منطقة شرق القاهرة قريباً

القاهرة 6 يوليو: أعلن المهندس عبد الله سلام – الرئيس التنفيذي لشركة مِنكَ للاستثمار العقاري، إحدى شركات عائلة سلام – أنه بصدد إطلاق أحدث وأكبر مشروعات الشركة خلال الشهر القادم في منطقة شرق القاهرة. كما تستهدف الشركة التوسع في منطقة غرب القاهرة والمناطق الساحلية. وقد جاءت فكرة المشروع استكمالاً للنجاح الذي حققته الشركة خلال الأربع سنوات الماضية بتقديم مشاريع مبتكرة ذات توجه مختلف، وكجزء من خطة الشركة في المساهمة في تطوير قطاع العقارات في مصر.

قال المهندس عبد الله سلام – الرئيس التنفيذي لشركة مِنكَ للاستثمار العقاري "فخورون بما قدمناه من مشاريع خلال فترة زمنية قصيرة حيث نجحنا في تكوين هوية خاصة بنا والسير بخطي ثابتة ومبتكرة لتبلغ الاستثمارات المرصودة للمشاريع الحالية قيد التطوير والإنشاء إلى 6 مليار جنيه مصري في الأربع سنين القادمة. نستهدف من خلال رؤيتنا التي تتمحور حول إسعاد المصريين والمساهمة في جعل مصر مكان أفضل من خلال بناء مجتمعات مبتكرة ومشاريع ذات بصمة معمارية مميزة ومواكبة لأحدث الأنماط العالمية التي ترتقي بالإنسانية والملائمة للتغيرات من وقت لآخر."

وأضاف سلام قائلا: "منذ تواجد الشركة في سوق العقارات المصري في عام 2016، قدمنا عدة مشاريع تستهدف عملاء لديهم رؤية مستقبلية مستدامة ومتطورة. وتتميز تلك المشاريع بجاهزيتها للتشغيل إما عن طريق الاستثمار أو الاستخدام المباشر وبتقديمها قيمة مضافة ليس فقط للعميل ولكن لسوق العقارات المصري ككل، وهو الأمر الذي يشجعنا على الاستمرارية وابتكار مشروعات أكثر تميزاً. "

وعلق سلام على قطاع العقارات المصري قائلاً: "على الرغم من التحديات التي يشهدها العالم كله والاقتصاد بصفة خاصة، إلا أن القطاع العقاري يعد من القطاعات التي لم تتوقف لحيوية المنتج العقاري في دورة الحياة وانه أفضل من قطاعات أخري تأثرت بشدة". معقباً: "نحن نؤمن أن من رحم الأزمات تخلق الفرص ونرى أن قطاع العقارات لديه فرص كبيرة للنمو وهو ما يمثل دافعاً رئيسياً لنا للابتكار. وأوضح أن شركة مِنكَ حرصت منذ بداية أزمة الكورونا على الإبقاء على جميع الموظفين والعاملين بالشركة ووضعت صحة وسلامة فريق العمل على رأس أولوياتها من خلال إتخاذ كافة الإجراءات الوقائية والاحترازية بمقر الشركة وجميع مواقع العمل، والذي جاء متوافقا مع توجه الدولة في رفع شعار لا لتعطيل حركة الإنتاج وعجلة التشييد والبناء."
جدير بالذكر أن شركة منكِ للاستثمار هي شركة مملوكة لعائلة السلام والتي يمتد تاريخها لأكثر من 80 عاماً في السوق المصري، ومن أبرز شركات و مشاريع العائلة أوليمبيك جروب بعلاماتها أوليمبيك إليكتريك و إيديال ، شركة بي تك أكبر سلسلة محلات أجهزة منزلية وإلكترونيات في مصر، والجامعات الكندية في مصر بأفرعها الثلاثة، وشركة منلو المصنعة لمنتجات تانك و كولدير، وشركة وصلة لخدمات التعهيد، و كيدزينيا مصر رائد صناعة التعليم الترفيهي في العالم، و OCL للخدمات اللوجستية والأفق الزراعية، وInPack لصناعة مواد التعبئة والتغليف وغيرهم، حيث أن العائلة معروفة ببناء صروح وعلامات تجارية مصرية مؤثرة، بجانب تأثيرها الإيجابي على الاقتصاد المصري، و مساهمتها في العمل العام من خلال مؤسسات بنك الطعام المصري و بنك الشفاء و بنك الكساء.


Honeywell’s Healthy Buildings solutions help building owners comply with new hygiene and social distancing policies and enable business continuity

Honeywell’s #HealthyBuildings Score provides owners with real-time insights based on indoor air quality, safety, security, sanitation and compliance metrics

Honeywell solutions can be tailored to the unique needs of commercial buildings, airports, hospitality, healthcare and education sectors, supporting the region’s return to the new normal

DUBAI, United Arab Emirates, July 7, 2020 – Honeywell (NYSE: HON) today announced an integrated solutions portfolio to help building owners in the Middle East improve the health of their building environments, operate more cleanly and safely, comply with social distancing policies, and help reassure occupants that it is safe to return to the workplace. By integrating air quality, safety and security technologies along with advanced analytics, Honeywell’s Healthy Buildings solutions are designed to help building owners minimize potential risks of contamination and create business continuity by monitoring both the building environment and building occupants’ behaviors.

Honeywell’s new solutions provide building owners with more control over critical health, safety and security factors to encourage sustained compliance with changing building standards, safety guidelines, government-issued regulations and a company’s risk management policies. These innovative solutions also provide transparency into a building’s health status to its occupants.

“We’re all facing a new normal – including how buildings are managed. We’re working with entities in the region to support well-being as building owners, operators and occupiers return to work, consider travel, visit shopping malls or healthcare facilities,” said George Bou Mitri, vice president and general manager, Honeywell Building Technologies, Middle East, Turkey and Africa. “Honeywell has developed outcome-based solutions that allow building owners in the region to transparently address how they limit exposure to and the spread of viruses while supporting their business continuity needs. We’re giving them the data they need to confidently reassure their employees to accelerate their business operations.”

Honeywell’s Healthy Buildings solutions are part of a comprehensive effort among Honeywell’s businesses to come together to quickly develop solutions that are helping important sectors of the global economy recover. Honeywell’s Healthy Buildings solutions provide a holistic view of a building’s health based on key factors such as indoor air quality, occupant flow, personal protection equipment (PPE) analytics, thermal screening, social distancing, anti-bacterial wiring devices and sanitation efficacy.

Honeywell’s Healthy Buildings solutions features two packages - one focused on indoor air quality and another on safety and security.

The Honeywell Healthy Buildings Air Quality package monitors, manages and controls key parameters to create a healthier built environment while still managing energy efficiency. The Air Quality package can:

Help building owners implement the latest local guidelines;

Manage pressurization, ventilation, temperature and humidity;

Gauge environmental and occupancy parameters;

Provide real-time insights on contaminant risk, alerts to change HEPA filters, cleaning and occupant behavior; and

Control and optimize UV sterilization, air filtration and air composition.

The Honeywell Healthy Buildings Safety & Security package features hardware and software that can help building owners minimize risk by monitoring, detecting and responding to potential issues using integrated security tools. The Safety & Security package can:

Manage people flow and reporting, people counting, proactive property protection, thermal temperature screening and PPE mask detection;

Monitor and help sustain compliance with social distancing, space sanitation; and

Support contact tracing due to potential virus exposure by leveraging advanced video analytics and incident management workflows.

In addition, Honeywell’s novel #HealthyBuildings Score analytics, provides real-time alerts to building owners and operators so they can quickly address non-compliance issues or deal with infection-related incidents. The #HealthyBuildings Score comprises key building health metrics that can be provided to occupants in a simplified view on a dashboard. Healthy Buildings outcomes are powered by Honeywell Forge and monitored via the #HealthyBuildings score.

The Honeywell Healthy Buildings solutions can support the needs of any building and features specific solutions for premium commercial buildings, airports, hospitality, banking, stadium, healthcare and education sectors. The fully integrated air quality, health, safety and security controls are backed by expert services and remote monitoring support. Customers can also leverage their existing infrastructure, including third-party solutions, to affordably enhance air quality and security outcomes.

Other businesses within Honeywell are introducing innovative new technologies to provide a healthier environment for customers and end users. For example, Honeywell recently announced temperature monitoring solutions, which can be rapidly deployed at the entryway of a factory, airport, distribution center, stadium or other commercial buildings to quickly and efficiently identify whether personnel exhibit an elevated facial temperature.

The company has also developed an Environment Control System Health check that allows airlines to quickly use aircraft data and advanced analytics to monitor for and improve cabin air quality. Additionally, it’s applying the Honeywell Forge platform to help customers operate their buildings, factories, warehouses, supply chains, and aircraft more efficiently and in ways that promote the health and safety of occupants, workers, and passengers.

Click here for more information on the Honeywell #HealthyBuildings solutions.

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)

Numab’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion

INGELHEIM, Germany & WAEDENSWIL, Switzerland--(BUSINESS WIRE/AETOSWire)-- Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.

Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

“We are thrilled to work with the excellent team at Numab to advance our portfolio assets. Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.

“We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. “The upfront payment and near-term milestones attached to this alliance will further strengthen Numab’s ability to accelerate the development of key proprietary assets.”

Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each area. Boehringer Ingelheim receives from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.

With today’s announcement, Numab has been able to secure seven ongoing relationships with leading pharmaceutical companies including 3SBio / Sunshine Guojian, Boehringer Ingelheim, Eisai Co., Ltd., CStone Pharmaceuticals, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., and Tillotts Pharma AG.

Please click on the following link for ‘Notes to Editors’:


View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005453/en/

Dubai achieves another milestone in healthcare with the launch of state-of-the-art cosmetic surgery hospital

New hospital opens in Dubai

Dr Marwan al Mulla, CEO, Health Regulation Sector said, “With a strong emphasis on world class healthcare and medical expertise, Dubai attracts health tourism from around the world”

Michael Davis, CEO of NMC Health said, “CosmeSurge takes pride in delivering the greatest level of clinical care through our experienced team of specialist consultants, doctors, nurses, and technicians”

Dubai, United Arab Emirates, 7 July, 2020, (AETOSWire): NMC Healthcare has officially launched its new CosmeSurge Hospital in Jumeirah. The facility, completed in December of last year, specialises in providing cosmetic surgeries, and is located near the iconic Burj Al Arab. This will be the 17th branch of the CosmeSurge brand of facilities.

The launch coincides with all the significant measures currently undertaken by the Emirate of Dubai towards bringing life back to normalcy, including the issuance of tourist visas which came into effect today.

The event will be attended by, NMC Health’s CEO Michael Davis, along with Saeeda Jaffar, Managing Director, Alvarez & Marsal Middle East Limited, Clancey Po, NMC Health’s Director of Corporate Operations Strategy, Dr Zuhair Al Fardan, President of Emirates Plastic Surgery Society and Caroline Stanbury, Influencer and Reality TV Star.

Speaking on the occasion, Michael Davis, CEO of NMC Health said, “CosmeSurge takes pride in delivering the greatest level of clinical care through our experienced team of specialist consultants, doctors, nurses, and technicians. CosmeSurge adopts the highest international standards for quality, safety, and privacy in carrying out cosmetic surgery and aesthetics procedures and we will be particularly diligent in ensuring patient safety as we begin to treat patients in our post-COVID environment. Patients will no longer be required to travel to the west for state-of-the-art treatment, as we bring the expertise of Beverly Hills to our patients here in Dubai.”

The AED 65 million hospital will cater to the increasing demand of cosmetic surgeries among residents and shall bolster medical tourism across the region, thus enhancing the image of Jumeirah Dubai as the hub of wellness tourism.

Dr Marwan al Mulla, CEO, Health Regulation Sector said, “With a strong emphasis on world class healthcare and medical expertise, Dubai attracts health tourism from around the world. Courtesy its well regulated environment, the Emirate also boasts of talented professionals from across the globe and continues to support investments in the healthcare industry that showcase the strength and ability of Dubai to provide the best treatment facilities for its residents and visitors.”

The sprawling gadget-heavy facility in Dubai is aesthetically built consisting of eight in-patient rooms, two of which are designated VIP suites. The specialist in-patient procedures provided include cosmetic/plastic surgery and aesthetic medicine including; reconstructive surgery, cosmetic gynaecology, liposuction, breast augmentation, tummy tuck, and nose reshaping. The hospital will also offer the latest in obesity treatment and management including weight loss surgery, nutritional management, and full body lift procedures.

دبي تشهد إطلاق مستشفى كوزمسيرج الأكثر حداثة في جميرا

الدكتور مروان الملا: تعزيز حركة السياحة العلاجية في دبي

مايكل ديفيس: إفتتاح مستشفى كوزمسيرج الجديد يعكس قدرة ومرونة دولة الإمارات في تفعيل كافة قطاعات الأعمال

دبي، الإمارات العربية المتحدة - 7 يوليو 2020، ("ايتوس واير"): أطلقت مجموعة ان ام سي للرعاية الصحية مستشفى كوزمسيرج الجديد في منطقة جميرا بدبي والذي تم الإنتهاء من تأسيسه في شهر ديسمبر العام الماضي، حيث يقع المرفق الجديد المتخصص في الجراحة التجميلية بالقرب من برج العرب الشهير، ويعد الفرع السابع عشر لكوزمسيرج في منطقة دول مجلس التعاون الخليجي.

ويتزامن هذا الإطلاق مع الخطوات الهامة التي تتخذها إمارة دبي لإعادة الحياة إلى طبيعتها والتي تتضمن إصدار التأشيرات السياحية التي دخلت حيز التنفيذ اليوم.

وقد تم افتتاح المستشفى الجديد بحضور مايكل ديفيس، الرئيس التنفيذي لشركة ان ام سي للرعاية الصحية، والدكتورة سعيدة جعفر، المديرة العامة لقسم تحسين الأداء الاستراتيجي في شركة "ألفاريز آند مارسال"، وكلانسي بو، مدير استراتيجية العمليات المؤسسية في شركة ان ام سي، بالإضافة إلى الدكتور زهير الفردان رئيس شعبة التجميل في جمعية الإمارات الطبية أستاذ الجراحة في كلية الطب والعلوم الصحية بجامعة الإمارات، وأخيراً كارولين ستانبيري، من الشخصيات الاجتماعية المؤثرة في وسائل التواصل الإجتماعي.

وقال مايكل ديفيس: "يشرفني أن أفتتح مستشفى كوزمسيرج الجديد في جميرا رسمياً، وهو ما يعكس قدرة ومرونة دولة الإمارات في تفعيل كافة قطاعات الأعمال بقوة وخاصة قطاع الرعاية الصحية على إثر جائحة فيروس كورونا. ومما لا شك فيه أن هذا المرفق الجديد سيجذب الاهتمام من جميع أنحاء العالم وسيسهم في النجاح المستمر للسياحة العلاجية في منطقة الشرق الاوسط".

وأضاف:" إن كوزمسيرج تفخر بتقديم أعلى مستوى من الرعاية السريرية من خلال فريقنا المتمرس من الاستشاريين والأطباء والممرضات والفنيين. وتعتمد كوزمسيرج أعلى المعايير الدولية للجودة والسلامة والخصوصية في إجراء عمليات التجميل والجراحة التجميلية وفق أسس وإجراءات تضمن سلامة المرضى، كما سيتم توفير خبرات بيفرلي هيلز في دبي وفق أعلى المعايير دون الحاجة إلى السفر خارج الدولة".

وسيعمل المستشفى الذي تبلغ تكلفته 65 مليون درهم إماراتي على تلبية الطلب المتزايد على جراحات التجميل بين مختلف فئات المجتمع من مقيمين وزائرين، بما يعزز من مكانة جميرا دبي كمركز للسياحة العلاجية.

وفي حديثه بهذه المناسبة، قال الدكتور مروان الملا، المدير التنفيذي لقطاع التنظيم الصحي في هيئة الصحة بدبي: "إن افتتاح المراكز المتخصصة الراقية الجديدة يدل على أنها تعمل بشكل فعال كالمعتاد في دولة الإمارات العربية المتحدة. ومن خلال تعزيز حركة السياحة العلاجية في دبي، نتوقع أن يجذب المستشفى الجديد اهتماماً كبيراً لكبار الجراحين من مختلف دول العالم الأمر الذي سيسهم في جلب أفضل الممارسات العالمية ضمن صناعة السياحة العلاجية".

وقد تم إنشاء المستشفى وفق أحدث طراز من الناحية المعمارية، وتضم 8 غرف للمرضى، اثنان منها عبارة عن أجنحة مخصصة لكبار الشخصيات. وتتضمن الإجراءات التخصصية للمرضى داخل المستشفى الجراحة التجميلية أو البلاستيكية، والطب التجميلي بما في ذلك؛ الجراحة الترميمية، والعميات التجميلية، وشفط الدهون، وتكبير الثدي، وشد البطن، وإعادة تشكيل الأنف، وسيقدم المستشفى أحدث علاج للسمنة وإدارتها، بما في ذلك جراحة إنقاص الوزن، وإدارة التغذية، وإجراءات شد الجسم بالكامل.